Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

Chimeric antigen receptor(CAR) T-cell therapy has shown remarkable effects and promising prospects in patients with refractory or relapsed malignancies, pending further progress in the next-generation CAR T cells with more optimized structure, enhanced efficacy and reduced toxicities. The clustered...

Full description

Saved in:
Bibliographic Details
Published inBriefings in functional genomics Vol. 19; no. 3; pp. 175 - 182
Main Authors Li, Chenggong, Mei, Heng, Hu, Yu
Format Journal Article
LanguageEnglish
Published England Oxford University Press 20.05.2020
Subjects
Rev Paper
CRISPR
genome editing
CAR T cells
Cas9
cancer immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Chimeric antigen receptor(CAR) T-cell therapy has shown remarkable effects and promising prospects in patients with refractory or relapsed malignancies, pending further progress in the next-generation CAR T cells with more optimized structure, enhanced efficacy and reduced toxicities. The clustered regulatory interspaced short palindromic repeat/CRISPR-associated protein 9 (CRISPR/Cas9) technology holds immense promise for advancing the field owing to its flexibility, simplicity, high efficiency and multiplexing in precise genome editing. Herein, we review the applications and explorations of CRISPR/Cas9 technology in constructing allogenic universal CAR T cells, disrupting inhibitory signaling to enhance potency and exploration of safer and more controllable novel CAR T cells.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2041-2657
2041-2649
2041-2657
DOI:10.1093/bfgp/elz042